Announced the presentation of clinical biomarker findings from a prospective pooled analysis of patients ...
Dynamic changes in PD-L1 expression on circulating cancer-associated macrophage-like cells (CAML) were significantly associated with progression-free survival and overall survival following immunotherapies including the BriaCell regimenFindings from a prospective pooled analysis of 111 heavily pretreated metastatic breast cancer patients support further evaluation of circulating CAML PD-L1 as a potential biomarker of clinical benefit from immunotherapiesPooled analysis includes patients from mul
Today announced that four abstracts featuring preclinical research from their respective immunotherapy ...
Independent DSMB reports no safety concerns to date and recommends continuing BriaCell's pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitorSeventh consecutive positive DSMB recommendation reinforces the favorable safety and tolerability of BriaCell's novel immunotherapy approachPhase 3 study is being conducted under FDA Fast Track designation, underscoring the substantial unmet need in metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2026 (GLOB
Detailed price information for Briacell Therapeutics Corp (BCT-T) from The Globe and Mail including charting and trades.
Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)BriaCell Phase 3 trial featured in Nature Medicine as “Eleven clinical trials that will shape medicine in 2026” PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that Memorial Sloan Kettering C
BriaCell Therapeutics (NASDAQ:BCTX) shares experienced a volatile session on Monday after the biotechnology company announced that its Bria-MEL+ melanoma vaccine candidate had reached an important genetic engineering milestone. The stock initially jumped 25% following the announcement before surrendering those gains later in the session, highlighting the market’s shifting reaction to the development-stage programme.
Cell-based immunotherapy program is designed to harness patients’ own immune systems Bria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific treatment without individualized manufacturingProgram builds on BriaCell’s experience in metastatic breast cancer and prostate cancer, further expanding its therapeutic vaccine platform Melanoma remains a significant unmet medical need, with approximately 112,000 new cases and 8,510 deaths expected in t
This is the newest page. Registered accounts read further back.